EMEA-000901-PIP03-16

  • Email
  • Help

Overview

Product details for Jakavi
Invented nameJakavi
Active substance

Ruxolitinib (phosphate)

Decision numberP/0349/2017
PIP numberEMEA-000901-PIP03-16
Pharmaceutical form(s)Oral use; Gastric use
Condition(s)/indication(s)

Treatment of acute Graft versus Host Disease (aGvHD)

Route(s) of administrationTablet; Age-appropriate dosage form
PIP applicant

Novartis Europharm Limited
Tel. +41613241111
E-mail: paediatric.enquiries@novartis.com

Decision typeW: decision granting a waiver in all age groups for all conditions/indications

Decision

Related information